BIOPHAGE PHARMA (fka BIPMF)

[oasdihf]

Biophage Pharma Completes successful pilot study with Alberta Agriculture and Food - Large-scale production of phages gets green light

08:30 EDT Tuesday, August 28, 2007

MONTREAL, Aug. 28 /CNW Telbec/ - (TSX.V: BUG) - Biophage Pharma Inc. (TSX.V: BUG "Biophage") is pleased to announce the signing of a follow-on contract with Alberta Agriculture and Food. As the direct result of a successful pilot study (previously announced on April 3, 2007), Biophage and Alberta Agriculture and Food have now entered into an agreement to proceed with the production of large-scale volumes of highly purified bacteriophage preparations in a fermentor.

Securing this contract marks the beginning of a new business opportunity for Biophage and strengthens its relationship with Alberta Agriculture and Food. The completion of this second contract will bring Biophage in a position to offer biotech companies working in this field, as well as food producers and distributors, the commercial volumes of bacteriophages required to prevent bacterial contaminations throughout the supply chain, from the farm field to packaged products on store shelves.

Since the landmark U.S. Food and Drug Administration ruling of August 2006 allowing the use of phage preparations on ready-to-use-meat products, Biophage has received several inquiries from food producers and distributors who recognize the commercial potential of bacteriophages as an innovative, safe and environmentally friendly solution for the control of bacterial contaminations.

Dr Rosemonde Mandeville, President and CEO said: "The successful completion of the pilot study and the signing of this follow-on contract with Alberta Agriculture and Food in just three months demonstrate that our technologies and know-how are sound and solidify our position as a leading provider of highly purified phages to the food industry and Biotech companies. We expect this production line to generate a continuous revenue stream in the coming years as more food producers and distributors incorporate phage therapy in their production chain in order to control and prevent bacterial contaminations."

About Biophage Pharma Inc.

Biophage is a Canadian biotechnology company focused on the development of innovative phage-based products and technologies for the detection, prevention and control of bacterial infections. Biophage operates three divisions: (1) The Immunotox Labs division, which provides services in Immunogenicity and Immunotoxicity, Beryllium sensitivity testing (BeLPT) and exclusive MELISA(R) testing for the detection of sensitization to more than 200 different allergens including metals, penicillin, gluten, pollens and more recently Lyme disease (Boreliosis); (2) The Biosensors division for the development and commercialization of Biosensors PDS(R); and (3) The Therapeutics division for the prevention and control of bacterial contaminations in the medical, veterinary and environment fields. Both the Biosensor and Phage therapy programs have been structured to deliver an environmentally safe solution for the early detection and rapid control of deadly microorganisms.

(www.biophagepharma.net; www.immunotoxlabs.net)


The TSX Venture Exchange does not accept responsibility for the adequacy

or accuracy of this release.

%SEDAR: 00014714EF

For further information: Rosemonde Mandeville, M.B., Ch.B., PhD., President and CEO, Biophage Pharma Inc., [phone], [e-mail]; Louis Guindon, Chief Financial officer, Biophage Pharma Inc., [phone], [e-mail]